LG Chemical Ltd

13 articles about LG Chemical Ltd

• AVEO Oncology, an LG Chem company, Earns Spot on Boston Globe's 2023 Top Places to Work List for Second Consecutive Year

  11/30/2023

  For the second year in a row, AVEO Oncology, an LG Chem company, has earned a spot on the Boston Globe's annual 'Top Places to Work in Massachusetts' list.

• AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders

  1/3/2023

  AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO’s Special Meeting of Stockholders “FOR” the adoption of the Agreement and Plan of Merger among LG Chem, Ltd., a subsidiary of LG Chem and AVEO.

• Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease

  12/15/2022

  Innovent Biologics and LG Chem Life Sciences announced that the two parties have entered into a strategic collaboration and license agreement regarding LG Chem's Tigulixostat, a late-stage novel non-purine xanthine oxidase inhibitor for the chronic management of hyperuricemia in patients with gout disease.

• LG Chem Renews License Triggering Payment to Avacta

  6/30/2022

  Avacta Group plc is pleased to announce that LG Chem Life Sciences, the life sciences division of the South Korean LG Group, has exercised its renewal option as part of the ongoing collaboration with Avacta, triggering a license renewal fee payment to Avacta of $2 million.

• LG Chem Life Sciences Innovation Center and LabCentral Announce the 2022 Golden Ticket Winner – Rubik Therapeutics

  5/25/2022

  , LG Chem Life Sciences Innovation Center announced that it has selected Rubik Therapeutics as the winner of their 2022 LabCentral Golden Ticket Program.

• LG CHEM TO SEEK INNOVATIVE IDEAS FOR SUSTAINABLE TECHNOLOGIES WORLDWIDE THROUGH 3rd GLOBAL INNOVATION CONTEST

  1/20/2021

  LG CHEM TO SEEK INNOVATIVE IDEAS FOR SUSTAINABLE TECHNOLOGIES WORLDWIDE THROUGH 3 rd GLOBAL INNOVATION CONTEST

• Avacta and LG Chem Life Sciences Expand Partnership

  8/18/2020

  Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences, the life sciences division of the South Korean LG Group, to include new programmes incorporating Avacta’s Affimer XT™ serum half-life extension system.

• 

  BioSpace Global Roundup, Nov. 14

  11/14/2019

  Companies from across the globe provide updates on their business and pipelines.

• LG Chem Life Sciences Expands Partnership with Avacta Group plc

  11/13/2019

  LG Chem selects second and third drug targets following rapid progress in first programme

• LG Chem to Seek Innovative Technology Ideas Worldwide through 2nd Global Innovation Contest

  7/25/2019

  LG Chem (KRX: 051910) announced on 25th that it will host the 2nd Global Innovation Contest (GIC) for leading universities and research institutions worldwide.

• PDC*line Pharma enters into a licensing agreement with leading Korean pharmaceutical company LG Chem to develop PDC*lung cancer vaccine in Asia

  3/20/2019

  PDC*line Pharma grants exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercialization of PDC*lung cancer vaccine for lung cancer

• LG Chem Hosts Global Innovation Contest 2018 (GIC 2018) "Finding Innovations to Change the World"

  6/18/2018

  LG Chem is exploring innovative technologies that will change the world.

• IONTAS Signs Collaboration Agreement With LG Chem, Ltd. to Identify Therapeutic Oncology Leads

  6/5/2018

  IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem, Ltd. and to further prove the biological activity of the antibodies.